Category - Developments

Developments

iBio and Fraunhofer USA conclude litigation and enter license agreement

iBio (NYSE American:IBIO) successfully resolved its lawsuit with Fraunhofer USA, confirming iBio’s ownership of certain intellectual property related to plant-based biopharmaceutical production. As part of the...

May 5, 2021

Developments

Hepion Pharma presents machine learning “learn and confirm” modeling strategy at NASH Congress

Hepion Pharmaceuticals (NASDAQ:HEPA) SVP of clinical pharmacology and analytics, Dr. Patrick Mayo, gave a virtual presentation entitled, “CRV431 – From Benchtop to Bedside Clinical Development” at the 4th Global NASH...

April 29, 2021

Developments

Three finalists named for 2021 Bloom Burton Award

Daniel Durocher, Ph.D., scientific co-founder of Repare Therapeutics; Carl Hansen, Ph.D., founder and CEO of AbCellera; and Hamed Shahbazi, chairman and CEO of WELL Health Technologies are the three finalists for the...

April 27, 2021

Developments

Seelos receives positive EMA orphan drug opinion for SLS-005 in ALS

Seelos Therapeutics (NASDAQ:SEEL) received a positive opinion on European orphan drug designation for SLS-005 in amyotrophic lateral sclerosis (ALS) from the EMA committee for orphan medicinal products. The positive...

April 20, 2021

Developments

Ripple Therapeutics treats first patient in DME, RVO Phase 2 trial

The first patient has been treated in Ripple Therapeutics’ RIPPLE-1 Phase 2 trial evaluating IBE-814 IVT, a proprietary intravitreal dexamethasone implant targeting inflammatory retinal diseases. RIPPLE-1 is a single...

April 20, 2021

Developments

MiMedx announces last patient visits in 3 late-stage musculoskeletal trials

MiMedx Group (NASDAQ:MDXG) announced that the last patients have completed their last clinical visits in two late-stage IND trials: Phase 3 studies of AmnioFix injectable as a potential treatment for plantar fasciitis...

April 19, 2021

Developments

TransMedics receives positive FDA advisory committee vote for OCS Heart System

The FDA’s Circulatory Systems Device Advisory Panel issued a favorable vote in support of approval of TransMedics Group’s (NASDAQ:TMDX) OCS Heart System to the FDA’s Office of Health Technology 2 (Cardiovascular...

April 7, 2021

Developments

IntelGenx ships first CBD filmstrip order to Heritage Cannabis

IntelGenx (TSXV:IGX; OTCQB:IGXT) completed its first shipment, consisting of 75,000 CBD filmstrips, to Heritage Cannabis Holdings (CSE:CANN) for the Canadian and Australian markets. The CBD filmstrips were produced at...

April 1, 2021

Developments

111, Inc., Jianming Pharma to develop chronic disease management platform in China

111, Inc. (NASDAQ:YI), a leading digital healthcare platform company in China, and Jianming Pharmaceutical Group signed a strategic cooperation agreement to develop an online chronic disease management platform for the...

March 25, 2021

Developments

Lineage presents additional interim data with OpRegen in dry AMD with GA

Lineage Cell Therapeutics (NYSE American, TASE:LCTX) presented new positive interim results from its ongoing, 24-patient Phase 1/2a clinical study of its lead product candidate, OpRegen, for the treatment of dry age...

March 23, 2021

Category - Developments

iBio and Fraunhofer USA conclude litigation and enter license agreement

Hepion Pharma presents machine learning “learn and confirm” modeling strategy at NASH Congress

Three finalists named for 2021 Bloom Burton Award

Seelos receives positive EMA orphan drug opinion for SLS-005 in ALS

Ripple Therapeutics treats first patient in DME, RVO Phase 2 trial

MiMedx announces last patient visits in 3 late-stage musculoskeletal trials

TransMedics receives positive FDA advisory committee vote for OCS Heart System

IntelGenx ships first CBD filmstrip order to Heritage Cannabis

111, Inc., Jianming Pharma to develop chronic disease management platform in China

Lineage presents additional interim data with OpRegen in dry AMD with GA

General

More